HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025
SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a ...
HUTCHMED (China) Limited: HUTCHMED Reports 2024 Full Year Results and Provides Business Updates
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED", the "Company" or "we") (HKEX: 13; Nasdaq/AIM: HCM) today reports its financial r ...
Scage's Long-delayed Nasdaq SPAC Listing Moves Forward
Scage appears poised to complete its long-delayed Nasdaq SPAC listing next month, pending shareholder approval.
GDS Holdings Limited Reports Fourth Quarter and Full Year 2024 Results
GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China, today announced its unaudited ...
HUTCHMED Reports 2024 Full Year Results and Provides Business Updates
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) ...
China Briefing16h
Key Takeaways from China’s 2025 Two Sessions – Policy Priorities, Annual Budget, and Legislative Plans
The China Two Sessions 2025 outlined key policy priorities, economic strategies, and legislative plans, with significant ...